FlowPath Lung Test for Lung Cancer Detection
This study is evaluating a new test called the FlowPath Lung Test. This test uses sputum samples (mucus coughed up from the lungs) to see if it can accurately find lung cancer in people who are at high risk. You might be able to join if you are between 50 and 80 years old, have a history of smoking, and have lung nodules (small growths) between 6 and 30 millimeters that were found by a low-dose CT scan (LDCT). The main goal is to see how well the FlowPath Lung Test can detect early-stage lung cancer. The study plans to enroll 2063 participants, but its current status is unclear.
- Study design
- This is an interventional study planning to enroll 2063 participants. It is evaluating a diagnostic test for lung cancer.
- What's involved
- You would provide a baseline sputum sample and be followed for up to 24 months. You would also receive standard medical care as determined by your institution.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 24 months after providing a baseline sputum sample.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
At a glance
Conditions
Where it's being run
11 sites across 8 statesStudy leadership
- Maria Zannes · STUDY_CHAIR · bioAffinity Technologies Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate FlowPath Lung Test Detection of Early-Stage Lung Cancer in SputumFrom Baseline Sputum Sample provided by subject through 24 months follow up period.
Evaluate the clinical performance (positive percent agreement \[PPA/sensitivity\] and negative percent agreement \[NPA/specificity\]) of the FlowPath Lung test in predicting lung cancer from the sputum of high-risk individuals with lung nodules